Four to buy
Dr. Martens
Shares in this British bootmaker have lost 75% of their value since 2021 after several profit warnings. While the record is discouraging, on nine times earnings the risks look priced in. Revenue has risen by an average of 14% per year since 2020, but the execution has been poor. If management does rectify operational problems, then there could be decent upside for the shares, but even if it fails to do so, the firm could well attract
